Wyselekcjonowana · Ochrona zdrowia

Biotech

Od InspectStocksPublished 14 paź 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Pogrupowane z pomocą modelu AI i sprawdzone przez naszą redakcję. Wiersz pod każdą spółką mówi, dlaczego się tu znalazła.

Download image

Karty Poziomy

Ceny akcji to kursy zamknięcia z 11 lis 2026, z notowań giełdy IEX.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap 138,7B USDP/E 35,22
547,02 USD+26,0%1Y
Since added +12,7%
B+
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mocna
Getting better
Poprawia się
Revenue
13B USD+10,5%
Profit
4B USD+8,2%
Free cash flow
3,2B USD-4,0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap 101,3B USDP/E 21,18
959,45 USD+41,5%1Y
Since added +27,4%
C+
Wzrost i gotówka
Rośnie
Business trend
Przyspiesza
Business quality
Mocna
Getting better
Poprawia się
Revenue
16,9B USD+18,6%
Profit
4,8B USD+5,2%
Free cash flow
3,8B USD-9,4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap 210,5B USDBrak C/Z (strata operacyjna)
169,73 USD+40,9%1Y
Since added +14,8%
A
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mieszana
Getting better
Poprawia się
Revenue
31B USD+6,5%
Profit
-3,9B USD-147,6%
Free cash flow
13,8B USD+50,4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap 21,4B USDP/E 68,58
159,80 USD-64,7%1Y
Since added -28,6%
B+
Wzrost i gotówka
Rośnie mocno
Business trend
Zwalnia
Business quality
Mocna
Getting better
Poprawia się
Revenue
3,7B USD+65,2%
Profit
2,6B USD+2136,9%
Free cash flow
465,4M USD+1192,7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap 37,5B USDP/E 109,22
253,39 USD+56,9%1Y
Since added +10,7%
A
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Solidna
Getting better
Mieszane
Revenue
10,3B USD+2,3%
Profit
347,5M USD-78,4%
Free cash flow
2,1B USD-10,1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap 26,5B USDBrak C/Z (strata operacyjna)
120,64 USD-37,9%1Y
Since added +24,7%
C-
Wzrost i gotówka
Rośnie
Business trend
Stabilny
Business quality
Słaba
Getting better
Mieszane
Revenue
1,5B USD+240,0%
Profit
-605,6M USD+48,8%
Free cash flow
-627,6M USD+30,7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap 25,4B USDP/E 22,48
595,58 USD+29,0%1Y
Since added +9,6%
C+
Wzrost i gotówka
Rośnie mocno
Business trend
Zwalnia
Business quality
Mocna
Getting better
Wyraźnie się poprawia
Revenue
3,2B USD+1,9%
Profit
1,2B USD-3,2%
Free cash flow
867,2M USD-22,7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap 17,6B USDP/E 25,87
174,35 USD+18,7%1Y
Since added +29,0%
A+
Wzrost i gotówka
Rośnie mocno
Business trend
Przyspiesza
Business quality
Mocna
Getting better
Poprawia się
Revenue
3,7B USD+38,0%
Profit
702,5M USD+64,1%
Free cash flow
1B USD+75,3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap 100,6B USDBrak C/Z (strata operacyjna)
248,70 USD+831,1%1Y
Since added +15,0%
C-
Wzrost i gotówka
Rośnie
Business trend
Przyspiesza
Business quality
Słaba
Getting better
Pogarsza się
Revenue
2,5B USD+13,1%
Profit
-2,8B USD+10,5%
Free cash flow
-2B USD+25,7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap 11,3B USDNo P/E
58,32 USD+5,4%1Y
Since added +7,3%
B
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mieszana
Getting better
Poprawia się
Revenue
3,7B USD+18,1%
Profit
-19,1M USD-103,7%
Free cash flow
557,9M USD-33,0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap 24,9B USDP/E 65,01
122,23 USD+12,9%1Y
Since added +12,6%
C
Zysk i wartość księgowa
Rośnie
Business quality
Mieszana
Getting better
Wyraźnie się poprawia
Revenue
6B USD+24,9%
Profit
403,4M USD-66,1%
Free cash flow
892,1M USDNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap 17,3B USDP/E 21,17
70,71 USD+62,2%1Y
Since added +18,8%
A+
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mocna
Getting better
Poprawia się
Revenue
2,5B USD+9,1%
Profit
885,1M USD+30,6%
Free cash flow
1,2B USD+48,9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap 22B USDBrak C/Z (strata operacyjna)
87,64 USD-21,5%1Y
Since added -1,5%
F
Wzrost i gotówka
Mieszane
Business trend
Kurczy się
Business quality
Mieszana
Getting better
Poprawia się
Revenue
2,7B USD-23,2%
Profit
-1,6B USD-157,7%
Free cash flow
314M USD+456,5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap 15,9B USDP/E 80,84
248,18 USD+81,5%1Y
Since added +18,0%
A
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mieszana
Getting better
Poprawia się
Revenue
4,7B USD+13,5%
Profit
206M USD+155,9%
Free cash flow
1,6B USD+21,3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap 11,6B USDP/E 25,36
101,69 USD+44,0%1Y
Since added -7,2%
A+
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mocna
Getting better
Poprawia się
Revenue
1,8B USD+45,0%
Profit
485,4M USD-18,5%
Free cash flow
885,9M USD+47,1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap 16,1B USDBrak C/Z (strata operacyjna)
259,10 USD+30,1%1Y
Since added +16,0%
D
Zysk i wartość księgowa
Mieszane
Business quality
Mieszana
Getting better
Poprawia się
Revenue
1,2B USD+113,4%
Profit
-254,8M USD+39,7%
Free cash flow
-293,2M USD+54,2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap 15,5B USDBrak C/Z (strata operacyjna)
79,53 USD+20,1%1Y
Since added +25,6%
B
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mieszana
Getting better
Pogarsza się
Revenue
945,5M USD+167,3%
Profit
-573,8M USD+28,6%
Free cash flow
-369,8M USD+36,9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap 8,2B USDP/E 58,68
74,52 USD-4,9%1Y
Since added -36,7%
A+
Wzrost i gotówka
Rośnie mocno
Business trend
Przyspiesza
Business quality
Mocna
Getting better
Mieszane
Revenue
963,6M USD+30,0%
Profit
162,3M USD+52,9%
Free cash flow
194,6M USD+19,2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap 9,2B USDP/E 41,90
308,82 USD+52,1%1Y
Since added -3,9%
A+
Wzrost i gotówka
Rośnie mocno
Business trend
Stabilny
Business quality
Mocna
Getting better
Poprawia się
Revenue
470M USD+26,0%
Profit
225,2M USD+13,2%
Free cash flow
310,1M USD+87,3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.